ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Sankyo, KAI in cardiac pact

January 16, 2006 | APPEARED IN VOLUME 84, ISSUE 3

Daiichi Sankyo and KAI Pharmaceuticals have formed a licensing agreement under which the Japanese firm will obtain development rights to KAI-9803, a cardiovascular drug candidate in Phase II clinical trials. Sankyo will pay KAI $20 million and milestone payments of up to $300 million. KAI may receive $20 million from Sankyo in research support over five years to identify new compounds, routes of administration, and indications for cardiovascular therapies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment